Publications by authors named "Ray Su"

Claim this Profile
A
A review of recent advances in data-driven computer vision methods for structural damage evaluation: algorithms, applications, challenges, and future opportunities.
Xiao Pan, Tony T Y Yang, Jun Li, Carlos Ventura, Christian Málaga-Chuquitaype, Ray Kai Leung Su

Arch Comput Methods Eng· April 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Novel accelerated carbonation methods based on deep breathing analogous and prediction model for pressurized carbonation of concrete.
Ray Kai Leung Su, Hao Li, Lijie Chen, Hongniao Chen

Sci Rep· October 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
V
Validation of a double-semicircular notched configuration for mechanical testing of orthodontic thermoplastic aligner materials.
Yuqing Zhang, Xiaozhuang Jin, Fabio Savoldi, Jianmin Han, Ray Kai Leung Su

J Mech Behav Biomed Mater· July 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Temporal Relationship Between Serum Neurofilament Light Chain and Radiologic Disease Activity in Patients With Multiple Sclerosis.
Robert J Fox, Bruce A C Cree, Jérôme de Sèze, Ralf Gold, Hans-Peter Hartung, Ray Su

Neurology· May 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Correction to: Improvements in Cognitive Processing Speed, Disability, and Patient‑Reported Outcomes in Patients with Early Relapsing‑Remitting Multiple Sclerosis Treated with Natalizumab: Results of a 4‑year, Real‑World, Open‑Label Study.
Jai Perumal, Roumen Balabanov, Ray Su, Roger Chang, Laura J Balcer

CNS Drugs· March 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Improvements in Cognitive Processing Speed, Disability, and Patient-Reported Outcomes in Patients with Early Relapsing-Remitting Multiple Sclerosis Treated with Natalizumab: Results of a 4-year, Real-World, Open-Label Study.
Jai Perumal, Roumen Balabanov, Ray Su, Roger Chang, Laura J Balcer

CNS Drugs· September 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Economic and caregiver impact of Alzheimer's disease across the disease spectrum: a cohort study.
Virginie Dauphinot, Michele Potashman, Mihaela Levitchi-Benea, Ray Su, Ivana Rubino

Alzheimers Res Ther· February 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
No evidence for loss of natalizumab effectiveness with every-6-week dosing: a propensity score-matched comparison with every-4-week dosing in patients enrolled in the Tysabri Observational Program (TOP).
Helmut Butzkueven, Ludwig Kappos, Tim Spelman, Maria Trojano, Heinz Wiendl, Ray Su

Ther Adv Neurol Disord· September 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Natalizumab in Early Relapsing-Remitting Multiple Sclerosis: A 4-Year, Open-Label Study.
Jai Perumal, Roumen Balabanov, Ray Su, Roger Chang, Laura Balcer

Adv Ther· July 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Correction to: Natalizumab in Early Relapsing-Remitting Multiple Sclerosis: A 4-Year, Open-Label Study.
Jai Perumal, Roumen Balabanov, Ray Su, Roger Chang, Laura Balcer

Adv Ther· July 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effectiveness of Dimethyl Fumarate in Patients With Relapsing Multiple Sclerosis Switching After Suboptimal Response to Glatiramer Acetate, Including Patients With Early Multiple Sclerosis: Subgroup Analysis of RESPOND.
Pavle Repovic, Derrick Robertson, Kiren Kresa-Reahl, Stanley L Cohan, Ray Su

Neurol Ther· June 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Real-world propensity score comparison of treatment effectiveness of peginterferon beta-1a vs. subcutaneous interferon beta-1a, glatiramer acetate, and teriflunomide in patients with relapsing-remitting multiple sclerosis.
Anthony T Reder, Nancy Arndt, Cortnee Roman, Caroline Geremakis, Jason P Mendoza, Ray Su

Mult Scler Relat Disord· June 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Real-world disability improvement in patients with relapsing-remitting multiple sclerosis treated with natalizumab in the Tysabri Observational Program.
Heinz Wiendl, Tim Spelman, Helmut Butzkueven, Ludwig Kappos, Maria Trojano, Ray Su

Mult Scler· April 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Clinical outcomes in patients who discontinue natalizumab therapy after 2 years in the Tysabri Observational Program (TOP).
Helmut Butzkueven, Maria Trojano, Ludwig Kappos, Tim Spelman, Heinz Wiendl, Ray Su

Mult Scler· March 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Matching comparisons of therapeutic efficacy suggest better clinical outcomes for patients treated with peginterferon beta-1a than with glatiramer acetate.
Thomas F Scott, Ray Su, Kuangnan Xiong, Arman Altincatal, Carmen Castrillo-Viguera

Ther Adv Neurol Disord· January 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Real-World Safety and Effectiveness of Dimethyl Fumarate in Hispanic or Latino Patients with Multiple Sclerosis: 3-Year Results from ESTEEM.
Angel Chinea, Lilyana Amezcua, Wendy Vargas, Annette Okai, Mitzi J Williams, Ray Su

Neurol Ther· December 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Real-World Safety and Effectiveness of Dimethyl Fumarate in Black or African American Patients with Multiple Sclerosis: 3-Year Results from ESTEEM.
Mitzi J Williams, Lilyana Amezcua, Annette Okai, Darin T Okuda, Stanley Cohan, Ray Su

Neurol Ther· December 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Association of Serum Neurofilament Light Levels With Long-term Brain Atrophy in Patients With a First Multiple Sclerosis Episode.
Tatiana Plavina, Carol M Singh, Dipen Sangurdekar, Carl de Moor, Bob Engle, Suzanne Szak, Ray Su

JAMA Netw Open· November 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Two parabolic-hyperbolic oriented partial differential equations for denoising in electronic speckle pattern interferometry fringes.
Wenjun Xu, Chen Tang, Junjiang Zhang, Yonggang Su, Ray Kai Leung Su

Appl Opt· May 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis